Dhvanit Shah, Garuda Therapeutics CEO
Blood stem cell therapy maker Garuda nabs $62M
Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.
The Boston-area biotech wants …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
